Lucid Diagnostics Inc. (LUCD)

Alpha Tau Medical (NASDAQ: DRTS - Get Free Report) and Lucid Diagnostics (NASDAQ: LUCD - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk and valuation. Insider and Institutional Ownership 2.7% of

Inogen (INGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare local coverage determination Series D Preferred Stock convertible into common stock subject to stockholder approval at an upcoming special meeting New senior secured note with three-year maturity yielded an additional $15 million of gross proceeds Proceeds used to redeem and retire all previously outstanding convertible securities, eliminating a significant legacy capital structure overhang Transactions yielded approximately $7.7 million in net cash proceeds, materially strengthening the Company's balance sheet NEW YORK, Feb. 4, 2026 /PRNewswire/ -- PAVmed Inc.  (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced the closing of preferred stock and senior secured note financings by existing long-term investors, resulting in the elimination of a significant legacy capital structure overhang from previously outstanding convertible securities and a materially strengthened balance sheet. The Company has issued $30 million of newly designated Series D Convertible Preferred Stock with warrants exercisable for up to an additional $30 million of Series D Convertible Preferred Stock, callable upon publication of a positive draft Medicare local coverage determination (LCD) for the EsoGuard Esophageal DNA Test offered by its subsidiary, Lucid Diagnostics, Inc. (Nasdaq: LUCD) ("Lucid").

NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has been awarded a contract by the U.S. Department of Veterans Affairs (VA) for its EsoGuard® Esophageal DNA Test , expanding access to esophageal precancer testing across the nation's largest integrated healthcare system, which serves more than nine million enrolled veterans annually. The contract is issued under the VA Federal Supply Schedule and includes pre-negotiated pricing for EsoGuard that matches the established Medicare payment rate determined by the Centers for Medicare & Medicaid Services (CMS), enabling VA hospitals and healthcare facilities nationwide to access EsoGuard through a single, national VA procurement framework.

Waters (NYSE: WAT - Get Free Report) and Lucid Diagnostics (NASDAQ: LUCD - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership. Earnings and Valuation This table compares Waters and Lucid

Lucid Diagnostics (NASDAQ: LUCD - Get Free Report) and Intuitive Surgical (NASDAQ: ISRG - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk. Earnings and Valuation This table compares Lucid Diagnostics

Report includes nearly 12,000 patients who underwent Lucid's EsoGuard® Esophageal DNA Test on samples collected using its EsoCheck® Esophageal Cell Collection Device Real-world data confirm excellent technical performance, very rapid cell-collection times, and appropriate physician use, consistent with previously published studies NEW YORK , Dec. 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced new data from the largest reported real-world experience of non-endoscopic esophageal precancer (Barrett's esophagus or BE) detection, which evaluated its EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device . The manuscript, entitled Non-Endoscopic Screening for Barrett's Esophagus Using a DNA Methylation-Based Assay: 18-Month Real-World Experience in 11,991 Patients , is currently available on the leading health sciences preprint server, medRxiv, while undergoing peer review for publication.

Recognized as the leading company in its size category in program honoring the top workplaces across the diagnostics and precision-medicine sectors NEW YORK , Nov. 20, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has been named the winner in its company size category of the GenomeWeb 2025 Best Places to Work program, one of five top-ranking honorees across the life sciences research, diagnostics and precision medicine sectors. GenomeWeb  is the leading news organization serving the global community of professionals in molecular biology research and molecular diagnostics.

Lucid Diagnostics Inc. (NASDAQ: LUCD - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year price

NEW YORK , Nov. 13, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, being held November 20, 2025 in New York City. Dennis McGrath, Lucid's Chief Financial Officer, will be available for one-on-one meetings with investors.

Veris Health launched commercial phase of strategic partnership and relaunched development of implantable physiological monitor PAVmed signed letter of intent (LOI) to license groundbreaking endoscopic esophageal imaging technology Conference call and webcast to be held today, November 13, at 8:30 AM EST NEW YORK , Nov. 13, 2025 /PRNewswire/ --  PAVmed Inc.  (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and reported financial results for the quarter ended September 30, 2025. Conference Call and Webcast The webcast will take place on Thursday, November 13, 2025, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.

Lucid Diagnostics Inc. ( LUCD ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Matthew Riley - Director of Investor Relations Lishan Aklog - Chairman & CEO Dennis McGrath - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG, LLC, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Anthony Vendetti - Maxim Group LLC, Research Division Joseph Conway - Needham & Company, LLC, Research Division Edward Woo - Ascendiant Capital Markets LLC, Research Division Presentation Operator Good morning, and welcome to the Lucid Diagnostics Third Quarter 2025 Business Update Conference Call. Please note, this event is being recorded.

Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.2 per share a year ago.

Processed 2,841 EsoGuard® tests and recognized 3Q25 revenue of $1.2 million, ending quarter with over $47 million in proforma cash and extending runway through 2026 and well past upcoming reimbursement milestones Multi-Jurisdictional Contractor Advisory Committee (CAC) meeting on Medicare Local Coverage Determination (LCD) for Lucid's EsoGuard yielded unanimous expert consensus supporting Medicare coverage Conference call and webcast to be held today, November 12, at 8:30 AM EST NEW YORK , Nov. 12, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the three months ended September 30, 2025. Conference Call and Webcast The webcast will take place on Wednesday, November 12, 2025, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , Oct. 30, 2025 /PRNewswire/ -- PAVmed Inc.  (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, November 13, 2025, at 8:30 AM ET. During the call,  Lishan Aklog, M.D.

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , Oct. 29, 2025 /PRNewswire/ --  Lucid Diagnostics Inc.  (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, November 12, 2025, at 8:30 AM ET. During the call,  Lishan Aklog, M.D.